S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The Small Biotech Scaring Big Pharma (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The Small Biotech Scaring Big Pharma (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The Small Biotech Scaring Big Pharma (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The Small Biotech Scaring Big Pharma (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
NASDAQ:ALEC

Alector - ALEC Stock Forecast, Price & News

$9.10
+0.66 (+7.82%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.18
$9.16
50-Day Range
$6.88
$9.55
52-Week Range
$6.84
$24.00
Volume
576,774 shs
Average Volume
561,596 shs
Market Capitalization
$752.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.71

Alector MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
94.7% Upside
$17.71 Price Target
Short Interest
Bearish
8.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.53) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

438th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

70th out of 171 stocks

ALEC stock logo

About Alector (NASDAQ:ALEC) Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Stock News Headlines

Alector Third Quarter 2022 Earnings: Misses Expectations
Morgan Stanley Downgrades Alector: Here's What You Need To Know
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Company Calendar

Last Earnings
11/08/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
208
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.71
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+94.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-36,330,000.00
Net Margins
-102.49%
Pretax Margin
-100.59%

Debt

Sales & Book Value

Annual Sales
$207.09 million
Book Value
$3.06 per share

Miscellaneous

Free Float
72,042,000
Market Cap
$752.57 million
Optionable
Not Optionable
Beta
0.94

Key Executives

  • Dr. Tillman Ulf Gerngross Ph.D. (Age 58)
    Co-Founder & Chairman
    Comp: $60k
  • Dr. Arnon Rosenthal Ph.D. (Age 66)
    Co-Founder, CEO & Director
    Comp: $972.75k
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 54)
    Pres and Head of R&D
    Comp: $552.78k
  • Mr. Calvin  YuMr. Calvin Yu (Age 46)
    VP of Fin.
    Comp: $519.69k
  • Dr. Robert S. KingDr. Robert S. King (Age 59)
    Chief Devel. Officer
    Comp: $658.84k
  • Dr. Marc Grasso M.D. (Age 48)
    Chief Financial Officer
  • Michelle Corral
    VP of Communications & Investor Relations
  • Ms. Danielle Pasqualone J.D.
    Ph.D., Interim Gen. Counsel
  • Erica Jefferson
    VP of Communications & Public Affairs
  • Ms. Clare Hunt M.B.A.
    Head of People













ALEC Stock - Frequently Asked Questions

Should I buy or sell Alector stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares.
View ALEC analyst ratings
or view top-rated stocks.

What is Alector's stock price forecast for 2023?

6 brokerages have issued 1-year target prices for Alector's stock. Their ALEC share price forecasts range from $6.00 to $41.00. On average, they anticipate the company's stock price to reach $17.71 in the next twelve months. This suggests a possible upside of 94.7% from the stock's current price.
View analysts price targets for ALEC
or view top-rated stocks among Wall Street analysts.

How have ALEC shares performed in 2022?

Alector's stock was trading at $20.65 at the start of the year. Since then, ALEC shares have decreased by 55.9% and is now trading at $9.10.
View the best growth stocks for 2022 here
.

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALEC earnings forecast
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) posted its earnings results on Tuesday, November, 8th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.13. The company had revenue of $14.85 million for the quarter, compared to analysts' expectations of $52.70 million. Alector had a negative net margin of 102.49% and a negative trailing twelve-month return on equity of 49.19%.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Who are Alector's major shareholders?

Alector's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.26%), Vanguard Group Inc. (6.96%), Federated Hermes Inc. (6.84%), State Street Corp (3.98%), Price T Rowe Associates Inc. MD (2.11%) and Renaissance Technologies LLC (0.87%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, David M Wehner, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Sabah Oney, Shehnaaz Suliman and Terrance Mcguire.
View institutional ownership trends
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $9.10.

How much money does Alector make?

Alector (NASDAQ:ALEC) has a market capitalization of $752.57 million and generates $207.09 million in revenue each year. The company earns $-36,330,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does Alector have?

The company employs 208 workers across the globe.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.

This page (NASDAQ:ALEC) was last updated on 12/4/2022 by MarketBeat.com Staff